Agios Pharmaceuticals Reports Strong Q1 Revenue Growth and Shares Rise 13%
Agios Pharmaceuticals (AGIO) reported first-quarter revenue of $20.7 million, a significant increase from $8.7 million in the same period last year, driven by the sales of its drug Aqvesme. The company's shares surged 13% following the earnings report, despite a net loss of $99 million. The FDA approved mitapivat for two blood disorders, contributing to the revenue growth.
Tickers: $AGIO
Topics: Earnings Report FDA Approval Revenue Growth Stock Performance